In 2022, the Centers for Medicare & Medicaid Services (CMS) finalized a coverage determination that severely restricts patient access to an entirely new class of therapies directed at the underlying cause of Alzheimer’s disease, even if the patient matches the criteria for the intended patient population. Let’s take a closer look at some of the barriers seniors with Alzheimer’s could face in attempting to access this class of treatments, with one such therapy already FDA-approved.